Works Cited

1. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction. 2008;103(9):1429-1440.

2. Darnall BD, Stacey BR, Chou R. Medical and psychological risks and consequences of long-term opioid therapy in women. Pain Medicine. 2012;13:1181-1211.

3. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Has Reviewed Possible Risks of Pain Medicine Use During Pregnancy. Available at Last accessed November 13, 2017.

4. Centers for Disease Control and Prevention. Prescription Painkiller Overdoses: A Growing Epidemic, Especially Among Women. Available at Last accessed November 13, 2017.

5. Mogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci. 2012;13(12):859-866.

6. Weimer MB, Macey TA, Nicolaidis C, Dobscha SK, Duckart JP, Morasco BJ. Sex differences in the medical care of VA patients with chronic non-cancer pain. Pain Med. 2013;14(12):1839-1847.

7. American Psychological Association. All Pain Is Not the Same: Psychologist Discusses Gender Differences in Chronic Pain. Available at Last accessed November 13, 2017.

8. Wu LT, Woody GE, Yang C, Blazer DG. Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2010;112(1-2):69-80.

9. Howard T. Heroin. San Diego, CA: Lucent Books; 2003.

10. Moss-King D. Unresolved Grief and Loss Issues Related to Heroin Recovery: Grief and Loss with Heroin Recovery. London: VDM Verlag; 2009.

11. Gutstein HB, Akil H. Opioid analgesics. In: Brunton L, Parker K, Lazo J, Buxton I, Blumenthal D (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011: 547-590.

12. Brezina C. Abuse and Society: Heroin, the Deadly Addiction. New York, NY: Rosen Publishing Group, Inc.; 2009.

13. Opioids: Pain Management, Addiction, Treatment, Effects and Information. Available at Last accessed November 13, 2017.

14. Stevens P. Introduction to substance abuse counseling. In: Stevens P, Smith RL (eds). Substance Abuse Counseling Theory and Practice. 5th ed. New York, NY: Pearson; 2013: 4-20.

15. Substance Abuse and Mental Health Services Administration. Detoxification and Substance Abuse Treatment Training Manual. Available at Last accessed November 13, 2017.

16. Centers for Disease Control and Prevention. Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification—New York City, 2012. MMWR. 2013;62(38);777-780.

17. Substance Abuse and Mental Health Services Administration. A Treatment Improved Protocol (TIP) 43: Medication–Assisted Treatment for Opioid Addiction During Pregnancy. Available at Last accessed November 13, 2017.

18. Nilsson L, Hamberger L. A Child is Born. 4th ed. New York, NY: Bantam Dell; 2004.

19. Lin-Fu JS. Neonatal Narcotic Addiction. Rockville, MD: U.S. Department of Health Education and Welfare; 1969.

20. Jansson LM, Velez M, Harrow C. The opioid exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009;5(1):47-55.

21. Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72(6):747-757.

22. American College of Obstetricians and Gynecologists Committee on Obstetric Practice, American Society of Addiction Medicine. ACOG committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81-e94.

23. Jones H, Heil SH, Arria AM, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107:5-27.

24. Cleary BJ, Donnelly J, Strawbridge J, et al. Methadone dose and neonatal abstinence syndrome: systematic review and meta-analysis. Addiction. 2010;105:2071-2084.

25. Franck LS, Harris SK, Soetenga DJ, Amling JK, Curley MAQ. The withdrawal assessment tool—version 1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatric Critical Care Medicine. 2008;9(6):573-580.

26. Savage SR, Schofferman J. Pharmacological therapies of pain in drug and alcohol addictions. In: Miller N, Gold M (eds). Pharmacological Therapies for Drug and Alcohol Addictions. New York, NY: Dekker; 1995: 373-409.

27. Wesson D, Smith D. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs. 2010;42(2):161-175.

28. Moss-King D. Individual treatment. In: Stevens P, Smith R (eds). Substance Abuse Counseling: Theory and Practice. 5th ed. New York, NY: Pearson; 2013: 188-201.

29. Soyka M. Buprenorphine use in pregnant opioid users: a critical review. CNS Drugs. 2013;27(8):653-662.

30. Newman RG, Gevertz SG. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis. 2011;30(4):318-322.

31. Centers for Disease Control and Prevention. Key Findings: Maternal Treatment with Opioid Analgesics and Risk for Birth Defects. Available at Last accessed November 13, 2017.

32. U.S. Food and Drug Administration. FDA Announces Enhanced Warnings for Immediate-Release Opioid Pain Medications Related to Risks Of Misuse, Abuse, Addiction, Overdose, and Death. Available at Last accessed November 13, 2017.

33. Ram A, Tuten M, Chisolm MS. Cigarette smoking reduction in pregnant women with opioid use disorder. J Addict Med. 2016;10(1):53-59.

34. Blandthorn J, Forster DA, Love V. Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of retrospective audit. Women Birth. 2011;24(1):32-39.

35. Hudak ML, Tan RC, the Committee on Drugs, the Committee on Fetus and Newborn of the American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-e560.

36. Tierney S. Identifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines. Available at Last accessed November 13, 2017.

37. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468-2479.

38. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013;102(11):1060-1066.

39. Finnegan, LP, Kron, RE, Connaughton, JF, Emich, JP, A scoring system for evaluation and treatment of the neonatal abstinence syndrome: a new clinical and research tool. In: Moriselli PL, Garattini S, Sereni F (eds). Basic and Therapeutic Aspects of Perinatal Pharmacology. New York, NY: Raven Press; 1975: 139-155.

40. Lindemalm S, Nydert P, Svensson JO, Stahle L, Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact. 2009;25(2):199-205.

41. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs.N Engl J Med. 2015;372(22):2118-2126.

42. Alhusen JL, Bullock L, Sharps P, Schminkey D, Comstock E, Campbell J. Intimate partner violence during pregnancy and adverse neonatal outcomes in low-income women. J Womens Health (Larchmt). 2014;23(11):920-926.

43. Ornoy A. The impact of intrauterine exposure versus postnatal environment in neurodevelopmental toxicity: long-term neurobehavioral studies in children at risk for developmental disorders. Toxicol Lett. 2003;140-141:171-181.

44. DeCristofaro JD, LaGamma EF. Prenatal exposure to opiates. Mental Retardation and Developmental Disabilities. 1995;1:177-182.

45. Gilboa SM, Salemi JL, Nembhard WN, Fixler DE, Correa A. Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006. Circulation. 2010;122(22):2254-2263.

46. Konijnenberg C, Melinder A. Neurodevelopmental investigation of the mirror neurone system in children of women receiving opioid maintenance therapy during pregnancy. Addiction. 2012;108(1):154-160.

47. Robertson SB, Weismer SE. Effects of linguistic and social skills in toddlers with delayed language development. J Speech Lang Hear Res. 1999;42(5):1234-1248.

48. Grim K, Harrison TE, Wilder RT. Management of neonatal abstinence syndrome from opioids. Clin Perinatol. 2013;40(3):509-524.

49. Moss-King. The Positive Direction Model: Opioid Use and Pregnancy. Bloomington, IN: AuthorHouse; 2017.

Evidence-Based Practice Recommendations Citations

1. World Health Organization. Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Geneva: World Health Organization; 2014. Summary retrieved from National Guideline Clearinghouse at Last accessed December 11, 2017.

Copyright © 2018 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.